Genkyotex : Financial visibility out to the beginning of 2020 - Results of phase II estimated for Q2 2019
>Cash position of € 10.2m at end-2018 - Financial visibility out to early-2020 - After the market close yesterday Genkyotex reported its cash position at end-December and gave an update on its phase II trial in primitive biliary cholangitis (PBC). The cash position stood at € 10.2m at end-December 2018, thus offering financial visibility out to the beginning of 2020. Note that the main item of expenditure is the phase II testing on GKT831 in PBC. This cash position is...Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.